Example: AstraZeneca conducted a clinical study exploring the question: "Can a stress test as a quasi anxiety-inducing situation show, whether a substance reduces anxiety?" If this were the case, the substance's therapeutic effectiveness 

could be proven with help of the stress test. In 2006, these study findings provided fundamental information on the topic. The one-time administration of a benzodiazepine suppresses the release of cortisol completely.


The experiences of stress, anxiety and exhaustion are closely related. Therefore, drug manufacturers develop active agents that are applied to treat anxiety and depression. These drugs should have the intended effect while remaining low-risk. This results in correspondingly large time and financial expenditures for the manufacturer. Only few active agents accomplish the journey from preclinical research to clinical trials, proving their harmlessness and therapeutic effectiveness for subsequent certification. Using founded contract research, daacro can provide your company with an early indication, in one direction or the other – helping you to reduce your time expenditure and to economically optimize your investment.

Psychoactive substances, for example, influence individual behaviour and experience through their effects on the central nervous system. Drug manufacturers develop, amongst others, anxiety-reducing substances, so- called anxiolytics. As an anxiety-inducing situation, our stress test can be integrated into an early phase of drug development (Phase I studies) and provide a timely indication of the therapeutic effectiveness. A published study that we conducted for AstraZeneca provides fundamental information on the topic.


Fries, E., Hellhammer, D. H. & Hellhammer, J. (2006). Attenuation of the hypothalamic-pituitary-adrenal axis responsivity to the Trier Social Stress Test by the benzodiazepine alprazolam. Psychoneuroendocrinology, 31: 1278-1288.